Health Care

TransMedics Group expands its transplant therapy leadership by moving into Assembly Innovation Park, securing 498,000 sq ft of state‑of‑the‑art biotech space to accelerate research, manufacturing, and investor engagement.

Vericel Corp projects $276 M revenue in 2025, led by 23 % Q4 MACI growth, showing strong traction in regenerative medicine and a $1.95 B market cap.

Avita Medical’s board reshuffle and modest stock rebound hint at untapped potential in its burn and wound‑care therapies, yet the stock remains heavily discounted.

NeuroPace reports 25% revenue growth in FY2025, with 2026 guidance projecting 20‑22% core RNS revenue growth and a strong market‑adoption outlook.

BriaCell Therapeutics shares volatile 2025 results, with its BriaVax breast‑cancer vaccine driving investor interest and a negative P/E yet strong market cap.

Vaxart’s pioneering oral flu vaccine tech sparks biotech buzz and investor interest—learn how gut‑stimulated immunity could reshape flu prevention and boost the company’s growth.

Explore Terns Pharmaceuticals’ latest moves in liver‑cancer drug development and market trends, plus key 2026 conference insights and investor outlook.

Discover how Carl Zeiss Meditec leads in ophthalmology tech and market trends—stock insights, global reach, and eye‑care innovation.

AtaiBeckley Inc. shares fall to $3.75 as the Nasdaq‑listed mental‑health biotech, linked to Berlin’s ATAI Life Sciences, projects 2026 growth amid a P/E of –4.88, a 5.98 P/B and a $1.36 bn market cap.

Rani Therapeutics (NASDAQ: RANI) is a volatile biotech with a $168M market cap, negative earnings, and mixed analyst views—buyers see upside, sellers warn of risk.